WO2008120765A1 - Analgesic composition - Google Patents
Analgesic composition Download PDFInfo
- Publication number
- WO2008120765A1 WO2008120765A1 PCT/JP2008/056239 JP2008056239W WO2008120765A1 WO 2008120765 A1 WO2008120765 A1 WO 2008120765A1 JP 2008056239 W JP2008056239 W JP 2008056239W WO 2008120765 A1 WO2008120765 A1 WO 2008120765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- propionic
- vitamin
- analgesic
- components
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
[PROBLEMS] To provide an analgesic composition which can enhances the analgesic effect of a propionic-acid-type analgesic agent such as ibuprofen contained therein and has excellent safety. [MEANS FOR SOLVING PROBLEMS] The composition comprises a propionic-acid-type analgesic agents and two or more vitamin B components. The total amount of the vitamin B components is preferably 0.001 to 100 parts by weight relative to 1 part by weight of the propionic-acid-type analgesic agent. The propionic-acid-type analgesic agent is preferably ibuprofen. The vitamin B components preferably comprise at least vitamin B12 or folic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007091793A JP5161472B2 (en) | 2007-03-30 | 2007-03-30 | Analgesic composition |
JP2007-091793 | 2007-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008120765A1 true WO2008120765A1 (en) | 2008-10-09 |
Family
ID=39808345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/056239 WO2008120765A1 (en) | 2007-03-30 | 2008-03-28 | Analgesic composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5161472B2 (en) |
WO (1) | WO2008120765A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018076305A (en) * | 2016-10-31 | 2018-05-17 | エスエス製薬株式会社 | Pharmaceutical composition |
WO2021037874A1 (en) * | 2019-08-26 | 2021-03-04 | Dsm Ip Assets B.V. | Solid oral dosage form comprising naproxen and vitamin b12 |
WO2021037871A1 (en) * | 2019-08-26 | 2021-03-04 | Dsm Ip Assets B.V. | Solid oral dosage form comprising naproxen and vitamin b6 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011168580A (en) * | 2010-01-19 | 2011-09-01 | Daiichi Sankyo Healthcare Co Ltd | Pharmaceutical composition |
JP6106359B2 (en) * | 2010-12-13 | 2017-03-29 | 第一三共ヘルスケア株式会社 | Solid formulation containing loxoprofen sodium and vitamin B1 |
JP7026457B2 (en) * | 2016-07-07 | 2022-02-28 | 第一三共ヘルスケア株式会社 | Oral pharmaceutical composition containing loxoprofen or a salt thereof and vitamins B12 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050028A1 (en) * | 1999-02-24 | 2000-08-31 | Andrew Peter Worsley | Compositions for the treatment of pain |
WO2000056404A1 (en) * | 1999-03-24 | 2000-09-28 | Kilgowan Limited | Formulations for treatment of pain comprising vitamin b12 and phenylanine |
-
2007
- 2007-03-30 JP JP2007091793A patent/JP5161472B2/en active Active
-
2008
- 2008-03-28 WO PCT/JP2008/056239 patent/WO2008120765A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050028A1 (en) * | 1999-02-24 | 2000-08-31 | Andrew Peter Worsley | Compositions for the treatment of pain |
WO2000056404A1 (en) * | 1999-03-24 | 2000-09-28 | Kilgowan Limited | Formulations for treatment of pain comprising vitamin b12 and phenylanine |
Non-Patent Citations (4)
Title |
---|
BRUGGEMAN G. ET AL.: "Results of a double-blind study of diclofenac + vitamin B1, B6, B12 versus diclofenac in patients with acute pain of the lumbar vertebrae", KLIN. WOCHENSCHR., vol. 68, no. 2, 1990, pages 116 - 120 * |
GLUECK C.J. ET AL.: "Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease", CLIN. APPL. THROMB. HEMOST., vol. 12, no. 4, 2006, pages 427 - 439 * |
O'SHAUGHNESSY J.A. ET AL.: "Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer", CLIN. BREAST CANCER, vol. 6, no. 2, 2005, pages 143 - 149 * |
TANAKA C.: "New Pharmacology, (4th revised edition)", 2002, NANKODO CO., LTD., pages: 484 - 485 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018076305A (en) * | 2016-10-31 | 2018-05-17 | エスエス製薬株式会社 | Pharmaceutical composition |
WO2021037874A1 (en) * | 2019-08-26 | 2021-03-04 | Dsm Ip Assets B.V. | Solid oral dosage form comprising naproxen and vitamin b12 |
WO2021037871A1 (en) * | 2019-08-26 | 2021-03-04 | Dsm Ip Assets B.V. | Solid oral dosage form comprising naproxen and vitamin b6 |
CN114302713A (en) * | 2019-08-26 | 2022-04-08 | 帝斯曼知识产权资产管理有限公司 | Solid oral dosage form comprising naproxen and vitamin B6 |
Also Published As
Publication number | Publication date |
---|---|
JP5161472B2 (en) | 2013-03-13 |
JP2008247822A (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008120765A1 (en) | Analgesic composition | |
GB0514463D0 (en) | Use of pinolenic acid | |
WO2008013840A3 (en) | Erastin analogs and uses thereof | |
IL195030A (en) | Dpp iv inhibitor formulations | |
WO2010054113A3 (en) | Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors | |
WO2007077560A3 (en) | Cryoprotective compositions and methods of using same | |
WO2010037059A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
WO2010003127A3 (en) | Antagonists of prostaglandin d2 receptors | |
WO2010042652A3 (en) | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors | |
WO2008082602A3 (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
WO2012103038A9 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
WO2009145989A3 (en) | Aminoalkylphenyl antagonists of prostaglandin d2 receptors | |
EP2123257A3 (en) | Stable high Vitamin C content polyol-in-oil emulsified system and its preparation | |
WO2009140642A3 (en) | Tricyclic antagonists of prostaglandin d2 receptors | |
WO2008070268A3 (en) | Pharmaceutical compositions | |
WO2010085820A3 (en) | Tricyclic compounds as antagonists of prostaglandin d2 receptors | |
CR10305A (en) | "SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE. | |
CL2013001482A1 (en) | Compounds derived from 3-methyl-7-oxo-4-thia-1-aza-bicyclo [3.2.0] heptane for use in inhibiting beta-lactamases produced by bacteria and restoring / enhancing the activity of antibiotics; and pharmaceutical composition that includes them. | |
WO2008113901A3 (en) | Composition with controlled release of levetiracetam and method for preparing same | |
WO2007044611A3 (en) | Methods for weight management | |
MX2011010547A (en) | Stable pharmaceutical compositions of diclofenac. | |
WO2008155651A3 (en) | Inositol for induction of ovulation | |
WO2009105853A3 (en) | Pharmaceutical combi-preparation comprising nootropic agents | |
WO2008070354A3 (en) | 5- and 6- substituted benzimidazole thiophene compounds | |
WO2011027344A3 (en) | Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08739357 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08739357 Country of ref document: EP Kind code of ref document: A1 |